Moderna (NASDAQ:MRNA) Price Target Increased to $135.00 by Analysts at Royal Bank of Canada

Moderna (NASDAQ:MRNA) had its target price hoisted by Royal Bank of Canada from $125.00 to $135.00 in a research report report published on Friday, Benzinga reports. They currently have an outperform rating on the stock.

MRNA has been the subject of several other reports. HSBC reiterated a reduce rating and set a $86.00 price target (up from $75.00) on shares of Moderna in a report on Monday, February 26th. William Blair restated a market perform rating on shares of Moderna in a report on Monday, April 1st. Needham & Company LLC reiterated a hold rating on shares of Moderna in a research note on Thursday, May 2nd. Jefferies Financial Group restated a buy rating and set a $125.00 price target on shares of Moderna in a research note on Tuesday, April 9th. Finally, Canaccord Genuity Group raised their price objective on Moderna from $82.00 to $91.00 and gave the stock a hold rating in a research report on Friday, February 23rd. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Moderna presently has a consensus rating of Hold and an average price target of $129.55.

Moderna Stock Down 2.3 %

NASDAQ MRNA opened at $122.13 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91. Moderna has a 12 month low of $62.55 and a 12 month high of $142.79. The company has a market capitalization of $46.81 billion, a P/E ratio of -7.79 and a beta of 1.57. The company’s 50 day simple moving average is $105.61 and its 200 day simple moving average is $94.76.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The company had revenue of $167.00 million during the quarter, compared to analyst estimates of $93.26 million. During the same quarter last year, the business posted $0.19 EPS. The company’s revenue for the quarter was down 91.0% on a year-over-year basis. Equities research analysts expect that Moderna will post -7.47 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Shannon Thyme Klinger sold 544 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $99.05, for a total value of $53,883.20. Following the completion of the transaction, the insider now directly owns 9,267 shares in the company, valued at approximately $917,896.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Shannon Thyme Klinger sold 544 shares of the business’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $99.05, for a total value of $53,883.20. Following the sale, the insider now owns 9,267 shares of the company’s stock, valued at $917,896.35. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $110.92, for a total transaction of $1,663,800.00. Following the completion of the transaction, the director now owns 2,026,931 shares in the company, valued at $224,827,186.52. The disclosure for this sale can be found here. Insiders sold a total of 139,954 shares of company stock valued at $14,822,576 over the last three months. Company insiders own 15.20% of the company’s stock.

Institutional Trading of Moderna

Institutional investors and hedge funds have recently modified their holdings of the business. Ogorek Anthony Joseph NY ADV acquired a new stake in shares of Moderna in the 4th quarter valued at approximately $27,000. Arlington Trust Co LLC boosted its position in Moderna by 4,833.3% in the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after buying an additional 290 shares in the last quarter. Westside Investment Management Inc. bought a new stake in shares of Moderna during the first quarter worth $32,000. Rise Advisors LLC increased its holdings in shares of Moderna by 953.3% during the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after buying an additional 286 shares in the last quarter. Finally, UMB Bank n.a. lifted its stake in shares of Moderna by 121.8% in the 1st quarter. UMB Bank n.a. now owns 366 shares of the company’s stock valued at $39,000 after acquiring an additional 201 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.